PTC Therapeutics (PTCT) stock on watch as company receives FDA approval for gene therapy Kebilidi for AADC deficiency. Read ...

Baird raised the firm’s price target on PTC Therapeutics (PTCT) to $48 from $44 and keeps an Outperform rating on the shares. The firm said 3Q24 revenue exceeded expectations meaningfully ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...

2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the treatment of AADC deficiency, ...

Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ...

BENGALURU: Nasdaq-list Nasdaq-listed global software company PTC is among the leading providers of product development ...

Raising and narrowing 2024 guidance ranges: Adjusted EBITDA of $750 to $780 million and Adjusted Free Cash Flow of $265 to $285 million. Reaffirming 2025 guidance ranges: Adjusted EBITDA of $925 to $1 ...

shares down 14% premarket PTC Therapeutics (NASDAQ:PTCT) slumps 14% premarket on increased volume in apparent response to the release of briefing documents ahead of Thursday's FDA Advisory ...

PTC Therapeutics (NASDAQ:PTCT) shares plunged more than 22% after-hours following topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich... After-Hours Stock Movers ...

Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Healthcare, Technology and Consumer Services sectors led shares lower. At the close in NYSE,... Investing.com ...